GlassScriptPhysician profile
Michael Allen Mckay
NPI 1649257858
$2,216.03
in general payments reported to CMS, 2019-2025
25 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $66.56 · 2021: $338 · 2022: $417 · 2023: $191 · 2024: $448 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.07 | 2019-2023 | |
| Ethicon US, LLC | $223.28 | 2024-2025 | Vistaseal, N/A |
| Pfizer INC. | $160.16 | 2022-2025 | |
| Merz North America, INC. | $139.41 | 2024 | |
| Janssen Pharmaceuticals, INC | $119.44 | 2022 | |
| Galderma Laboratories, L.P. | $119.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $115.25 | 2019 | |
| Mayne Pharma Commercial LLC | $106.51 | 2023-2025 | |
| Organon LLC | $75.45 | 2021-2024 | Nexplanon |
| Sage Therapeutics, LLC | $73.80 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $73.57 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.22 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $59.93 | 2023-2024 | Myfembree |
| Avion Pharmaceuticals | $58.62 | 2020-2023 | Balcoltra |
| Agile Therapeutics, INC. | $56.77 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $55.48 | 2021-2022 | |
| Astellas Pharma US INC | $54.00 | 2019-2024 | Veozah |
| Hologic Sales and Service, LLC | $49.93 | 2020-2024 | Myosure Tissue Removal Device |
| Aspira Women'S Health INC | $48.05 | 2021 | |
| Millicent US INC | $36.06 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Allergan, INC. | $28.31 | 2019-2022 | |
| Therapeuticsmd, INC. | $26.34 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.52 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.18 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.